RETINA-AI has developed and released the very first Artificial Intelligence mobile app for eye-care providers. This app — Fluid Intelligence by RETINA-AI — detects macula edema and sub-retinal fluid on O.C.T retinal scans with greater than ninety percent accuracy.
Both macula edema and sub-retinal fluid are key disease features that may indicate the presence of any number of retinal diseases including: diabetic macula edema, exudative macular degeneration, cystoid macula edema after cataract surgery, retinal vein occlusion macula edema, central serous chorioretinopathy, uveitic macula edema, and macula-off retinal detachments. Fluid Intelligence by RETINA-AI is therefore an excellent screening tool for any one of these diseases.
Fluid Intelligence by RETINA-AI will help eye-care professionals by providing high quality specialized retina care guidance at the click of a button. For instance, if an optometrist has a patient in the clinic who has macula degeneration, and is unsure if the macula degeneration is actively-wet or not, the optometrist can take a picture of the O.C.T. retinal scan and get a prediction as to whether that patient urgently needs an eye injection or not. To provide the clinical prediction, Fluid Intelligence uses expert A.I. algorithms running in the Cloud.
There are currently less than 3000 retinal specialists in the U.S. and even much less than that per capita in most other countries of the world. Therefore having some guidance on which cases are most urgent for referral is important.
RETINA-AI’s Founder, CEO, and Chief Software Architect, Dr. Stephen G. Odaibo is himself a retina specialist and board-certified ophthalmologist. In addition, he is the only ophthalmologist in the world with advanced degrees in both mathematics and computer science. He says that Fluid Intelligence by RETINA-AI has broken ground by showing how A.I. can enhance access to eye-care. “We are proud to be the very first in eye-care in the world to bring the power of A.I. to mobile devices in the clinic. Our overall goal is to increase access to high quality specialized retina care around the world.”
Original copy can be found here
